Since 1996 WHN is the second oldest medical website on the net, second only to the American Medical Association, servicing over 35,000 physicians and scientists worldwide.

A4M Medicine Redefined

Non-Profit Trusted Source of Non-Commercial Health Information

Kailera emerges wit...
 
Notifications
Clear all

Kailera emerges with $400m to advance next-generation weight loss drugs

1 Posts
1 Users
0 Reactions
32 Views
Posts: 1
Guest
Topic starter
(@Dr. Know)
New Member
Joined: 3 weeks ago

With Novo Nordisk continuing to break sales records with its obesity and diabetes drugs Wegovy and Ozempic, investment in weight loss drug development shows no signs of slowing up. Boston-based biotech Kailera Therapeutics is the latest player to enter the arena, emerging with a whopping $400 million Series A funding round to advance a portfolio of therapies for “obesity and related conditions.”

Kailera is developing both injectable and oral treatments that have already shown promise in clinical-stage trials. The company’s pipeline has been exclusively licensed from Chinese pharma giant Jiangsu Hengrui Pharmaceuticals for global development and commercialization outside of China.

https://longevity.technology/news/kailera-emerges-with-400m-to-advance-next-generation-weight-loss-drugs/

Leave a reply

Author Name

Author Email

Title *

My Media   or drag and drop it here. Max file size 50MB
 
Preview 0 Revisions Saved